NeuroOne Medical Technologies Corporation promotes Emily Johns to Chief Administrative Officer and General Counsel.
ByAinvest
Thursday, Oct 16, 2025 9:40 am ET1min read
NMTC--
Dave Rosa, President and CEO of NeuroOne, expressed his satisfaction with Johns' contributions to the organization, stating, "In the short time that Emily has been with NeuroOne, she has made impactful contributions to the organization and the future growth of the business. We look forward to her future contributions as we continue to scale our business." The report echoed the company's positive assessment of her early impact.
Johns, an experienced public company lawyer, is excited about her new role. She commented, "I am honored to step into this role and continue building on the strong foundation our exceptional team has created. As we look ahead, I look forward to strengthening our operations and infrastructure to help bring our life-changing technologies to more people." The MarketScreener piece provided these direct remarks from Johns.
Ms. Johns brings a wealth of experience to her new role. She previously served as a partner at Honigman LLP, where she represented many companies in the life sciences industry, including NeuroOne on all transactional work since 2017. Before that, she began her career at Sullivan & Cromwell LLP, where she represented public companies in securities offerings and M&A transactions. She received her J.D. from UCLA School of Law and her bachelor's degree from the University of Michigan, as noted in the announcement.
NeuroOne Medical Technologies Corporation is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, stimulation, and ablation for patients suffering from neurological disorders. The company aims to improve patient outcomes and reduce procedural costs. NeuroOne may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence, according to the same announcement.
NeuroOne Medical Technologies Corporation has promoted Emily Johns to Chief Administrative Officer and General Counsel, expanding her role to oversee human resources, compliance, security, and risk areas. Johns joined the company earlier this year as General Counsel and will continue to lead the legal strategy. As CAO, she will help strengthen operations and infrastructure to bring the company's life-changing technologies to more people.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has announced the promotion of Emily Johns to the expanded role of Chief Administrative Officer (CAO) and General Counsel. Johns, who joined NeuroOne earlier this year as its General Counsel, will continue to lead the legal strategy for the company. Additionally, she will now oversee all human resources, compliance, security, and risk areas of the organization, according to a MarketScreener report.Dave Rosa, President and CEO of NeuroOne, expressed his satisfaction with Johns' contributions to the organization, stating, "In the short time that Emily has been with NeuroOne, she has made impactful contributions to the organization and the future growth of the business. We look forward to her future contributions as we continue to scale our business." The report echoed the company's positive assessment of her early impact.
Johns, an experienced public company lawyer, is excited about her new role. She commented, "I am honored to step into this role and continue building on the strong foundation our exceptional team has created. As we look ahead, I look forward to strengthening our operations and infrastructure to help bring our life-changing technologies to more people." The MarketScreener piece provided these direct remarks from Johns.
Ms. Johns brings a wealth of experience to her new role. She previously served as a partner at Honigman LLP, where she represented many companies in the life sciences industry, including NeuroOne on all transactional work since 2017. Before that, she began her career at Sullivan & Cromwell LLP, where she represented public companies in securities offerings and M&A transactions. She received her J.D. from UCLA School of Law and her bachelor's degree from the University of Michigan, as noted in the announcement.
NeuroOne Medical Technologies Corporation is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, stimulation, and ablation for patients suffering from neurological disorders. The company aims to improve patient outcomes and reduce procedural costs. NeuroOne may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence, according to the same announcement.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet